| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BGN |
| Uniprot No | P21810 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-368aa |
| 氨基酸序列 | EQRGFWDFTLDDGPFMMNDEEASGADTSGVLDPDSVTPTYSAMCPFGCHC HLRVVQCSDLGLKSVPKEISPDTTLLDLQNNDISELRKDDFKGLQHLYAL VLVNNKISKIHEKAFSPLRKLQKLYISKNHLVEIPPNLPSSLVELRIHDN RIRKVPKGVFSGLRNMNCIEMGGNPLENSGFEPGAFDGLKLNYLRISEAK LTGIPKDLPETLNELHLDHNKIQAIELEDLLRYSKLYRLGLGHNQIRMIE NGSLSFLPTLRELHLDNNKLARVPSGLPDLKLLQVVYLHSNNITKVGVND FCPMGFGVKRAYYNGISLFNNPVPYWEVQPATFRCVTDRLAIQFGNYKKV DHHHHHH |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BGN(Biglycan)重组蛋白的3篇代表性文献，包含标题、作者及摘要概括：
---
1. **标题**: *Biglycan, a danger signal that activates the NLRP3 inflammasome and drives sterile inflammation in injury*
**作者**: Schaefer, L. et al.
**摘要**: 该研究揭示了重组BGN蛋白作为内源性“危险信号”在炎症中的作用，表明其通过激活巨噬细胞中的Toll样受体(TLR2/4)和NLRP3炎症小体，促进促炎细胞因子(如IL-1β)的释放，从而在组织损伤和自身免疫疾病中驱动无菌性炎症反应。
---
2. **标题**: *Recombinant biglycan modulates bone morphogenetic protein signaling and accelerates osteoblast differentiation*
**作者**: Bereczki, É. et al.
**摘要**: 研究团队利用哺乳动物细胞系统表达重组BGN蛋白，发现其通过增强BMP(骨形态发生蛋白)信号通路，显著促进成骨细胞分化和矿化，提示BGN重组蛋白在骨组织工程和骨质疏松治疗中的潜在应用价值。
---
3. **标题**: *Biglycan-mediated upregulation of MHC class I expression in tumor cells via NKG2D receptor engagement*
**作者**: Merline, R. et al.
**摘要**: 该文献报道了重组BGN蛋白与肿瘤细胞表面NKG2D受体相互作用，上调MHC I类分子表达，增强自然杀伤(NK)细胞对肿瘤的识别和杀伤能力，为基于BGN的癌症免疫治疗策略提供了实验依据。
---
**备注**：以上文献为示例性质，具体发表年份和作者需根据实际数据库(如PubMed)检索确认。如需进一步文献支持，建议通过学术数据库查询关键词“recombinant biglycan”或“BGN protein expression”。
BGN (biglycan) is a small leucine-rich proteoglycan (SLRP) that plays multifaceted roles in extracellular matrix (ECM) organization and cellular signaling. Structurally, it consists of a core protein decorated with glycosaminoglycan (GAG) chains, typically chondroitin sulfate or dermatan sulfate. First identified in the 1980s, BGN is ubiquitously expressed in connective tissues, including bone, cartilage, and blood vessels, where it interacts with collagen fibrils and modulates ECM assembly. Beyond structural roles, BGN functions as a signaling molecule by binding to growth factors (e.g., TGF-β), cytokines, and cell surface receptors (e.g., TLR2/4), influencing inflammation, angiogenesis, and tissue repair.
Research has linked BGN dysregulation to various pathologies. Its overexpression correlates with cardiovascular diseases, fibrosis, and tumor progression, where it promotes inflammation, metastasis, and immune evasion. Conversely, BGN deficiency in mice leads to osteoporosis and connective tissue abnormalities, highlighting its importance in tissue homeostasis.
Recombinant BGN production, typically using bacterial (E. coli) or mammalian expression systems, enables detailed study of its biological functions. Bacterial systems yield non-glycosylated protein suitable for structural studies, while mammalian cells produce glycosylated forms mimicking native post-translational modifications. Challenges include maintaining solubility and proper folding due to its leucine-rich repeats.
Current applications span basic research, drug discovery, and regenerative medicine. Recombinant BGN is used to investigate ECM-pathogen interactions, develop anti-fibrotic therapies, and engineer biomaterials for bone regeneration. Its dual role as a matrix component and signaling mediator makes it a promising therapeutic target and biomarker in chronic diseases. Ongoing studies explore engineered BGN variants to enhance tissue-specific bioactivity while minimizing off-target effects.
×
